| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Long QT syndrome (LQTS) is caused by hereditary cardiac channelopathies characterized by prolonged QT interval on an electrocardiogram. LQTS may precipitate malignant arrhythmia, resulting in syncope and sudden death. Genetic testing is currently utilized to assist treatment selection and prognostication with limited success. The predicted phenotype of the genetic abnormality often does not match the clinical phenotype due to low penetrance and variable expressivity of the syndrome.
we used LQTS patient-specific induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iPSC-CMs) and multi-electrode array (MEA) as a diagnostic platform for high-throughput in vitro phenotype screening. From our experimental results, a diagnosis protocol using iPSC-CM and MEA system may enable evaluation of channelopathies more accurately than genetic testing alone and to avoid ethical problems arising from revealing individual genes.
|
